Precise measurement of the gut microbiome empowers new discoveries in research and the development of innovative treatments and diagnostics.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Published study found a method designed for preserving forensic DNA outperformed other commonly used faecal preservation methods.
Microba Community Profiler (MCP) outperforms existing profilers for accurate and comprehensive characterisation of the human gut microbiome.
Microba Life Sciences, is empowering global consumer goods company Unilever to explore links between sleep and the human gut.
Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission.
The partnership's first clinical trial will determine if a new treatment can restore beneficial gut microbiome species and improve symptoms.
Bringing Microba’s world-leading metagenomic sequencing and bioinformatics together with Holobiome’s promising microbiome therapeutic pipeline.
Microba have partnered with Europe’s largest pathology provider, SYNLAB, to deliver leading gut microbiome analysis into Europe.
Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).